While small-molecule PAD4 inhibitors show promise in preclinical studies of targeting RA, they often lack specificity and potency due to direct targeting of the enzyme’s active site that is highly conserved across PAD isoforms12–14. This evidence concerns the gene PADI4 and rheumatoid arthritis.